Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

473 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz.
Covino DA, Purificato C, Catapano L, Galluzzo CM, Gauzzi MC, Vella S, Lefebvre E, Seyedkazemi S, Andreotti M, Fantuzzi L. Covino DA, et al. Among authors: andreotti m. Front Immunol. 2018 Aug 8;9:1839. doi: 10.3389/fimmu.2018.01839. eCollection 2018. Front Immunol. 2018. PMID: 30135687 Free PMC article.
A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease.
Floridia M, Bucciardini R, Ricciardulli D, Fragola V, Pirillo MF, Weimer LE, Tomino C, Giannini G, Galluzzo CM, Andreotti M, Cargnel A, Alberici F, De Rienzo B, Leoncini F, Fiaccadori F, Francisci D, Grillone W, Ortona L, Piazza M, Scalzini A, Nigra E, Tumietto F, Vella S. Floridia M, et al. Among authors: andreotti m. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):11-9. doi: 10.1097/00042560-199901010-00002. J Acquir Immune Defic Syndr Hum Retrovirol. 1999. PMID: 9928724 Clinical Trial.
Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients.
Bucciardini R, Wu AW, Floridia M, Fragola V, Ricciardulli D, Tomino C, Weimer LE, Pirillo MF, Mirra M, Marzi M, Giannini G, Galluzzo CM, Andreotti M, Massella M, Vella S; Istituto Superiore di Sanità 047 Study. Bucciardini R, et al. Among authors: andreotti m. AIDS. 2000 Nov 10;14(16):2567-74. doi: 10.1097/00002030-200011100-00020. AIDS. 2000. PMID: 11101069 Clinical Trial.
A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.
Floridia M, Tomino C, Bucciardini R, Ricciardulli D, Fragola V, Pirillo MF, Amici R, Giannini G, Galluzzo CM, Andreotti M, Seeber AC, Ammassari A, Cingolani A, Lazzarin A, Scalise G, Cargnel A, Suter F, Milazzo F, Pastore G, Moroni M, Ciammarughi R, Pini R, Carosi G, D'Amato C, Contu L, Concia E, Bonazzi L, Aiuti F, Vigevani G, Vella S; ISS-IP1 Clinical Investigators. Floridia M, et al. Among authors: andreotti m. AIDS Res Hum Retroviruses. 2000 Nov 20;16(17):1809-20. doi: 10.1089/08892220050195775. AIDS Res Hum Retroviruses. 2000. PMID: 11118067 Clinical Trial.
Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm(3)).
Floridia M, Massella M, Bucciardini R, Perucci CA, Rossi L, Tomino C, Fragola V, Ricciardulli D, Galluzzo CM, Giannini G, Pirillo MF, Andreotti M, Mirra M, Vella S. Floridia M, et al. Among authors: andreotti m. HIV Clin Trials. 2000 Sep-Oct;1(2):9-16. doi: 10.1310/6ulm-xyb7-h4xp-bhfj. HIV Clin Trials. 2000. PMID: 11590493 Clinical Trial.
HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/microL): an analysis of 338 clinical events from a randomized clinical trial.
Floridia M, Fragola V, Galluzzo CM, Giannini G, Pirillo MF, Andreotti M, Tomino C, Vella S. Floridia M, et al. Among authors: andreotti m. HIV Med. 2002 Apr;3(2):75-84. doi: 10.1046/j.1468-1293.2002.00104.x. HIV Med. 2002. PMID: 12010353 Free article. Clinical Trial.
Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL).
Floridia M, Bucciardini R, Fragola V, Galluzzo CM, Giannini G, Pirillo MF, Amici R, Andreotti M, Ricciardulli D, Tomino C, Vella S; ISS-IP1 study group. Floridia M, et al. Among authors: andreotti m. HIV Med. 2004 Jan;5(1):1-10. doi: 10.1111/j.1468-1293.2004.00177.x. HIV Med. 2004. PMID: 14731162 Free article. Clinical Trial.
473 results